PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Overview of attention for article published in Breast Cancer Research, March 2019

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 92 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 792 followers.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. - PubMed - NCBI https://t.co/JEauqHJVCe

18 Aug 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.